Additionally, exploration of the combined use of SLC7A11 inhibitors with existing chemotherapy agents, targeted therapy drugs, and immune checkpoint inhibitors may offer enhanced anti-tumor efficacy. Here, SLC7A11 is linked to neoplasm.